[1]
Rommer PS, Zettl UK. Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNS. Curr Pharm Des 2022; 28(6): 427.
[2]
Svačina MKR, Lehmann HC. Chronic inflammatory demyelinating polyneuropathy (CIDP): current therapies and future approaches. Curr Pharm Des 2022; 28(11): 854-62.
[3]
Glaubitz S, Zeng R, Rakocevic G, Schmidt J. Update on Myositis Therapy: from Today’s Standards to Tomorrow’s Possibilities. Curr Pharm Des 2022; 28(11): 863-80.
Current Pharmaceutical Design
Title:Current Pharmaceutical Trends in Neuroimmunology – Part II: Autoimmunity Beyond the CNS and Other Disorders
Volume: 28 Issue: 11
Author(s): Paulus S. Rommer and Uwe K. Zettl
Affiliation:
Export Options
About this article
Cite this article as:
Rommer S. Paulus and Zettl K. Uwe, Current Pharmaceutical Trends in Neuroimmunology – Part II: Autoimmunity Beyond the CNS and Other Disorders, Current Pharmaceutical Design 2022; 28 (11) . https://dx.doi.org/10.2174/138161282811220531104017
DOI https://dx.doi.org/10.2174/138161282811220531104017 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
12
1
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements